Iqstel vs Picocela
Iqstel is the larger business, with $317m of revenue in fiscal 2025 against $3.7m for Picocela (86.7 times as much). Iqstel grew faster (11.9% against -30.0%). Iqstel kept more of each dollar of sales as profit: a net margin of -2.7% against -115.0%. Iqstel carries less debt relative to equity (25.7% against 113.7%).
| Latest fiscal year | IqstelIQST, 2025 | PicocelaPCLA, 2025 |
|---|---|---|
| Revenue | $317m | $3.7m |
| Revenue growth | 11.9% | -30.0% |
| Net income | −$8.5m | −$4.2m |
| Operating margin | -1.3% | -110.4% |
| Net margin | -2.7% | -115.0% |
| Return on equity | -60.4% | -148.7% |
| Free cash flow | −$4.0m | −$3.8m |
| Cash | $2.2m | $3.6m |
| Total debt | $4.2m | $3.6m |
| Debt to equity | 25.7% | 113.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 100 | — |
| Market value | $8.3m | $8.1m |
| Price vs our value range | — | — |
| Moat score | 15 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |